Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir

Figure 2

Frequency of infant adverse events at birth by maternal protease inhibitor. Bars represent the percentage of infants with a laboratory adverse event of any grade (a) or the percentage of infants whose most severe adverse event was represented by that particular grade (b). Number of infants per group: atazanavir ± ritonavir (16), lopinavir/ritonavir (54), and nelfinavir (35). Hgb, hemoglobin; ANC, absolute neutrophil count; plts, platelet count; AST, aspartate aminotransferase; ALT, alanine aminotransferase. (95% CI 1.4–39.0), ; (95% CI 1.2–267.8), ; (95% CI 1.7–66.4), ; (95% CI 1.0–17.5), ; (95% CI 1.9–14.9), .

(a)

(b)